Member Info for Soupdragon78

Ralovatt, as I’ve shown you the workings, they make less money with the sp being lower.
Look at the other companies they subscribe in, they always sell regularly to cover the cost.

The way I showed you means they end the 20 month period with 27.5m shares for free no matter what the share price does.

So as an investment company would you want shares for free or to pay for them?

Ralovatt, the one thing you are missing is that Lanstead already have the shares, they are not buying any more no matter what the price.

The holdings rns on 21 December tells you they own the shares already.

And if they sold 5.5m at 0.75p how much profit would Lanstead make?

So, your saying when the sp is 1p and Lanstead owe NFX £41,250, they will sell at 0.75p?

Ralovatt.
Can you tell me how many shares Lanstead would hold at 0.75p per share?

Ralovatt,
Here how it works.
Lanstead already have the shares (see RNS on 21st December 2021) for the first tranche of 22m (+2m for Lanstead themselves)
They effectively have paid 1.5p for each of these shares and promised the proceeds to NFX against a base price of 2p.

Lanstead will not be buying any shares.

So, they have the shares and pledge the proceeds (£330k being 22m x 1.5p) to the company in 4 equal monthly payments.

This means that if the sp stayed bang on the 2p base price, NFX would get £82,500 each month for 4 months (£330k/4)

So, if Lanstead have to pay NFX the £82,500 where do they get that money? They either pay from their own coffers (highly unlikely) or they sell their shares and pass the money across.

So, to pay NFX £82,500 with a 2p base price, they could sell 5.5m shares at 2p for £110,000, give NFX the £82,500 and pocket the difference as profit.
Or they could sell 4,125,000 to get the £82,500 and pass it on to NFX and Lanstead keep the spare 1,375,000 shares.

As we see, Lanstead hold the shares and sell to pay NFX.

Now, what about the difference scenario of the share price?

If the sp was 1p for the settlement (50% below 2p base), Lanstead would owe NFX £41,250, so if they sold 5.5m then Lanstead would net £13,750 to themselves.
But if the sp was 3p. (50% above 2p base), Lanstead would owe NFX £123,750. But given they could sell 5.5m shares for 3p they would net profit £41,250 to themselves.

If the sp was 5p (250% above 2p base) Lanstead owe NFX £206,250 and Lanstead net profit is £151,250.

If you could post your workings Rav, that would be great.

No probs older. As always I may be wrong, but I’ve been wracking my tiny brain to try and figure out what’s going on.

Thanks Older, the ask price is the price someone is willing to sell shares to us at. Usually its the MM's.

On level two you will see their advertised price they are happy to sell shares for us to buy, say 1p.

Recently, there has been someone with Direct Market Access, they pop up separate to the MM's. and they recently place their Ask at say 0.95p. So, by my reckoning they are willing to sell to you at this price.

Over a period of time if no-one comes in and buys them, they take it away and then put it back at say 0.9p.

Eventually this gets taken up and the trade goes through at that price. The problem is, the MM's then move their Ask down towards this level.

This worked in the exact opposite in the run up to 1.6p a few weeks ago. Someone kept adding to the Bid above the MM's level, i.e. they wanted people to sell them stock at that point. They then kept moving it up, pulling up the MM's bid with them.

Approximately 3 months from the start date, so the first settlement dates is any time now. They use the 20 day VWAP to calculate the price that they pay to NFX.

The cynical person you cite would be incorrect. Its not in Lansteads interest for the shareprice to be low. They already have the shares.
They make more money with a higher shareprice.

For the past couple of weeks, someone has been selling into the market below the ask price and moves it down through the day undercutting the price MM's will sell at.
They've offloaded a few million this way.

Filter, you'll be glad to know that they spent lunchtime updating the advisors page on the website.

“ The continuing pursuit of international patent filings by its US based patent agent will also require the extra funds that the Lanstead Subscription is expected to provide. Once obtained NXP004 will be a valuable asset for out-licensing.”

From 17 Jan Circular.

They said they will do further work on it before approaching the originator.

Wonder if we are in the near future yet?

Always glad to help.

I know where you're coming from Chab, it is annoying that nothing more came out of it, although it feels more like they tried to figure out a cocrystal to work with AV-101, but no success.

Nothing untoward, just the science didn't work in that instance.

£95k from Vista.

The 'NFX Live RNS' button above

Click on the 'news' button and have a look.

NXP001 is at the same point of development as NXP002, both are seeking to commence phase 1 trials by the end of the year.

At the time when oxilio were granted their option, yes 001 was further along, but they have spend the past year reformulating it to work with the TRx encapsulation method.

So now they are at the same stage, setting up non-glp toxicology studies.

It was Blackwell who fixed the terms of the deal, it seems they were all set at the beginning and not negotiable.